Brokerages forecast that KemPharm Inc (NASDAQ:KMPH) will announce earnings of ($0.28) per share for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for KemPharm’s earnings, with the lowest EPS estimate coming in at ($0.29) and the highest estimate coming in at ($0.27). KemPharm reported earnings per share of ($0.94) in the same quarter last year, which suggests a positive year over year growth rate of 70.2%. The firm is scheduled to announce its next quarterly earnings results on Thursday, November 14th.
According to Zacks, analysts expect that KemPharm will report full year earnings of ($1.25) per share for the current financial year, with EPS estimates ranging from ($1.28) to ($1.21). For the next year, analysts forecast that the firm will post earnings of ($0.02) per share, with EPS estimates ranging from ($0.35) to $0.32. Zacks’ EPS averages are an average based on a survey of research analysts that cover KemPharm.
KemPharm (NASDAQ:KMPH) last issued its quarterly earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($0.33) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.42) by $0.09.
Several analysts have commented on KMPH shares. Roth Capital cut KemPharm from a “buy” rating to a “neutral” rating and lowered their price target for the company from $4.25 to $1.05 in a report on Thursday, September 5th. ValuEngine upgraded KemPharm from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Zacks Investment Research upgraded KemPharm from a “hold” rating to a “buy” rating and set a $0.50 price target for the company in a report on Friday, October 25th. Finally, HC Wainwright restated a “buy” rating and issued a $3.00 price target on shares of KemPharm in a report on Thursday, September 5th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $1.89.
KemPharm stock traded down $0.02 during midday trading on Friday, reaching $0.50. The company’s stock had a trading volume of 58,300 shares, compared to its average volume of 175,182. The firm has a market capitalization of $18.62 million, a PE ratio of -0.20 and a beta of 1.39. The stock’s 50 day simple moving average is $0.63 and its 200 day simple moving average is $1.17. KemPharm has a fifty-two week low of $0.45 and a fifty-two week high of $3.00.
In other KemPharm news, CEO Travis C. Mickle purchased 50,000 shares of the stock in a transaction on Tuesday, September 24th. The stock was bought at an average price of $0.79 per share, for a total transaction of $39,500.00. Following the acquisition, the chief executive officer now directly owns 1,713,117 shares of the company’s stock, valued at $1,353,362.43. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders acquired a total of 73,000 shares of company stock valued at $58,237 in the last 90 days. 14.90% of the stock is owned by company insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in shares of KemPharm by 134.5% in the 2nd quarter. Vanguard Group Inc. now owns 1,337,571 shares of the specialty pharmaceutical company’s stock valued at $2,341,000 after purchasing an additional 767,100 shares in the last quarter. Wedbush Securities Inc. lifted its stake in shares of KemPharm by 738.5% in the 3rd quarter. Wedbush Securities Inc. now owns 97,430 shares of the specialty pharmaceutical company’s stock valued at $67,000 after purchasing an additional 85,810 shares in the last quarter. BlackRock Inc. lifted its stake in shares of KemPharm by 21.7% in the 2nd quarter. BlackRock Inc. now owns 106,490 shares of the specialty pharmaceutical company’s stock valued at $186,000 after purchasing an additional 19,001 shares in the last quarter. Iowa State Bank lifted its stake in shares of KemPharm by 90.6% in the 2nd quarter. Iowa State Bank now owns 44,171 shares of the specialty pharmaceutical company’s stock valued at $77,000 after purchasing an additional 21,000 shares in the last quarter. Finally, RDA Financial Network acquired a new position in shares of KemPharm in the 2nd quarter valued at about $28,000. 25.44% of the stock is currently owned by institutional investors and hedge funds.
KemPharm, Inc, a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. The company's product candidate includes KP415 and KP484 for the treatment of attention deficit hyperactivity disorder; and KP879 for the treatment of stimulant use disorder.
Featured Story: Understanding Market Liquidity
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.